Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Adults With T-allo10 Cells Addback
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of a cell therapy, T-allo10, after
αβdepleted-HSCT in the hopes that it will boost the adaptive immune reconstitution of the
patient while sparing the risk of developing severe Graft-versus-Host Disease (GvHD).
The primary objective of Phase 1 is to determine the recommended Phase 2 dose (RP2D)
administered after infusion of αβdepleted-HSCT in children and young adults with hematologic
malignancies.
A Phase 1b extension will occur after dose escalation, enrolling at the RP2D for the T-allo10
cells determined in the Phase 1 portion to evaluate the safety and efficacy of infusion of
T-allo10 after receipt of αβdepleted-HSCT. Additionally, Phase 1b aims to explore
improvements in immune reconstitution.
All participants on this study must be enrolled on another study: NCT04249830